Successful treatment with reduced-intensity stem cell transplantation in a case of relapsed refractory central nervous system lymphoma

Annals of Hematology

Volumn 82, Issue 6, 2003, Pages 371-373

  Aoyama, Yasutaka ^a   Yamamura, R ^a   Shima, E ^a   Nakamae, H ^a   Makita, K ^a   Kho, G ^a   Ohta, K ^a   Yamane, T ^a   Takubo, T ^a   Hino, M ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Allogeneic stem cell transplantation; Central nervous system lymphoma; Graft versus lymphoma effect; Reduced intensity stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RANIMUSTINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; VINCRISTINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CASE REPORT; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; LYMPHOCYTE; MALE; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PARALYSIS; PRIORITY JOURNAL; REFRACTORY PERIOD; SIBLING; TUMOR REGRESSION;

ADULT; BIOPSY; BRAIN NEOPLASMS; HUMANS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; RECURRENCE; STEM CELL TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 10744229246     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0651-z     Document Type: Article

References (10)

1. Lazarus HM, Loberiza FR Jr, Zhang MJ, et al. (2001) Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 27:387-396
2. Czyz J, Hellmann A, Dziadziuszko R, et al. (2002) High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 30:29-34
3. Ratanatharathorn V, Uberti J, Karanes C, et al. (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050-1055
4. van Besien KW, Mehra RC, Giralt SA, et al. (1996) Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 100:299-307
5. Ferme C, Mounier N, Divine M, et al. (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 20:467-475
6. van Besien KW, de Lima M, Giralt SA, et al. (1997) Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19:977-982
7. Slavin S, Nagler A, Naparstek E, et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763
8. Hale GA, Phillips GL (2000) Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease. Cancer Treat Rev 26:411-427
9. Kogel KE, McSweeney PA (2002) Reduced-intensity allogeneic transplantation for lymphoma. Curr Opin Oncol 14:475-483
10. Varadi G, Or R, Kapelushnik J, et al. (1999) Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma 34:185-190